Abstract
Evidence on effectiveness and safety of sirolimus in congenital vascular anomalies in infancy is lacking. We aim to systematically review the efficacy and safety of sirolimus in treating congenital VA in infancy. We searched for and included all studies evaluating sirolimus for VA in the first year of life. The primary outcome was effectiveness. The secondary outcome was safety. We included 84 case series and reports (172 participants). Sirolimus decreased the size of the VA in >50% of participants, most of whom had minor transient side effects, and 27% had no adverse effects at all. When categorized by age (<1 month, 1–5 months and 6–12 months), the effectiveness was similar in all age groups. Available evidence suggests that sirolimus is effective and well tolerated. The effectiveness of sirolimus should be evaluated in a well-designed randomized controlled or observational studies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
All data generated or analyzed during this study are included in this published article and its supplementary information files.
References
Sepulveda A, Buchanan EP. Vascular tumors. Semin Plast Surg. 2014;28:49–57.
Adams DM, Trenor CC 3rd, Hammill AM, Vinks AA, Patel MN, Chaudry G, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 2016;137:e20153257.
Carqueja IM, Sousa J, Mansilha A. Vascular malformations: classification, diagnosis and treatment. Int Angiol. 2018;37:127–42.
Gallant SC, Chewning RH, Orbach DB, Trenor CC 3rd, Cunningham MJ. Contemporary management of vascular anomalies of the head and neck-part 1: vascular malformations: a review. JAMA Otolaryngol Head Neck Surg. 2021;147:197–206.
ISSVA. ISSVA Classification of Vascular Anomalies ©2018 International Society for the Study of Vascular Anomalies. Available at issva.org/classification. 2018.
Triana P, Dore M, Cerezo VN, Cervantes M, Sanchez AV, Ferrero MM, et al. Sirolimus in the treatment of vascular anomalies. Eur J Pediatr Surg. 2017;27:86–90.
Sehgal SN, Baker H, Vézina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot. 1975;28:727–32.
Hammer J, Seront E, Duez S, Dupont S, Van Damme A, Schmitz S, et al. Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study. Orphanet J Rare Dis. 2018;13:191.
Mizuno T, Emoto C, Fukuda T, Hammill AM, Adams DM, Vinks AA. Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies. Eur J Pharm Sci. 2017;109s:S124–s31.
Emoto C, Fukuda T, Mizuno T, Schniedewind B, Christians U, Adams DM, et al. Characterizing the developmental trajectory of sirolimus clearance in neonates and infants. CPT Pharmacomet Syst Pharmacol. 2016;5:411–7.
Meier-Kriesche HU, Kaplan B. Toxicity and efficacy of sirolimus: relationship to whole-blood concentrations. Clin Ther. 2000;22(Suppl B):B93–100.
Nadal M, Giraudeau B, Tavernier E, Jonville-Bera AP, Lorette G, Maruani A. Efficacy and safety of mammalian target of rapamycin inhibitors in vascular anomalies: a systematic review. Acta Derm Venereol. 2016;96:448–52.
Hammill AM, Wentzel M, Gupta A, Nelson S, Lucky A, Elluru R, et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer. 2011;57:1018–24.
Ricci KW, Hammill AM, Mobberley-Schuman P, Nelson SC, Blatt J, Bender JLG, et al. Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham-Stout disease. Pediatr Blood Cancer. 2019;66:e27614.
Vahidnezhad H, Youssefian L, Uitto J. Klippel-Trenaunay syndrome belongs to the PIK3CA-related overgrowth spectrum (PROS). Exp Dermatol. 2016;25:17–9.
di Blasio L, Puliafito A, Gagliardi PA, Comunanza V, Somale D, Chiaverina G, et al. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations. Cell Death Dis. 2018;9:45.
Alomar S, Khedr RE, Alajlan S. CLOVES syndrome in a nine-month-old infant. Cureus. 2019;11:e5772.
Hughes M, Hao M, Luu M. PIK3CA vascular overgrowth syndromes: an update. Curr Opin Pediatr. 2020;32:539–46.
Canaud G, Hammill AM, Adams D, Vikkula M, Keppler-Noreuil KM. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations. Orphanet J Rare Dis. 2021;16:306.
Moola SMZ, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, et al. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris EMZ, editor. Joanna Briggs Institute Reviewer’s Manual. The Joanna Briggs Institute; 2020. Available from: https://synthesismanual.jbi.global.
Alaqeel AM, Alfurayh NA, Alhedyani AA, Alajlan SM. Sirolimus for treatment of Kaposiform hemangioendothelioma associated with Kasabach-Merritt phenomenon. JAAD Case Rep. 2016;2:457–61.
Alemi AS, Rosbe KW, Chan DK, Meyer AK. Airway response to sirolimus therapy for the treatment of complex pediatric lymphatic malformations. Int J Pediatr Otorhinolaryngol. 2015;79:2466–9.
Ameel K, Turner TL. Chylous effusion in an infant: presenting symptom of lymphangiomatosis. Am J Respir Crit Care Med. 2018;197:A5603.
Amodeo I, Colnaghi M, Raffaeli G, Cavallaro G, Ciralli F, Gangi S, et al. The use of sirolimus in the treatment of giant cystic lymphangioma: four case reports and update of medical therapy. Medicine. 2017;96:e8871.
Asante A. Use of rapamycin in complicated vascular tumors. Pediatr Blood Cancer. 2014;61:S15.
Azouz H, Salah H, Al-Ajlan S, Badran M. Treatment of cystic hygroma in a young infant through multidisciplinary approach involving sirolimus, sclerotherapy, and debulking surgery. JAAD Case Rep. 2016;2:350–3.
Boccara O, Hadj-Rabia S, Bourrat E, Coulombe J, Bodemer C. Rapamycin-associated lymphoedema in an infant with Kasabach-Merritt phenomenon. Br J Dermatol. 2016;174:933–4.
Cabrera TB, Speer AL, Greives MR, Goff DA, Menon NM, Reynolds EW. Sirolimus for Kaposiform Hemangioendothelioma and Kasabach-Merritt Phenomenon in a Neonate. Am J Perinatol Rep. 2020;10:e390–e4.
Cashell J, Smink GM, Helm K, Xavier F. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon in an infant: successful treatment with prednisolone, vincristine, and addition of sirolimus. Pediatr Blood Cancer. 2018;65:e27305.
Chetan C, Patnaik S, Suryawanshi P, Garegrat R. Sirolimus used for treatment of retroperitoneal arteriovenous malformation in a premature neonate. BMJ Case Rep. 2022;15:08.
Chinello M, Di Carlo D, Olivieri F, Balter R, De Bortoli M, Vitale V, et al. Successful management of Kaposiform Hemangioendothelioma with long-term sirolimus treatment: a case report and review of the literature. Mediterr J Hematol Infect Dis. 2018;10:e2018043.
Clark H, Schulte R, Haggstrom AN. Severe hypertriglyceridemia following sirolimus use in an infant. Pediatr Dermatol. 2021;38:1581–2.
Curry S, Logeman A, Jones D. Sirolimus: a successful medical treatment for head and neck lymphatic malformations. Case Rep Otolaryngol. 2019;2019:2076798.
Davila-Osorio VL, Iznardo H, Roe E, Puig L, Baselga E. Propranolol-resistant infantile hemangioma successfully treated with sirolimus. Pediatr Dermatol. 2020;37:684–6.
Duan L, Renzi S, Weidman D, Waespe N, Chami R, Manson D, et al. Sirolimus treatment of an infant with intrathoracic Kaposiform Hemangioendothelioma complicated by life-threatening pleural and pericardial effusions. J Pediatr Hematol Oncol. 2020;42:74–8.
Ersoy AO, Oztas E, Saridogan E, Ozler S, Danisman N. An unusual origin of fetal lymphangioma filling right axilla. J Clin Diagn Res. 2016;10:QD09–11.
Escoda AC, Ramos MGL, Suárez JA, Celma MS, Heredia AC, Passini VPC. DI-040 use of sirolimus in a newborn affected by lymphatic malformation. Eur J Hosp Pharm Sci Pract. 2017;24:A130–A1.
Favia A. Kasabach-Merritt syndrome in a newborn: from prenatal diagnosis with MRI To treatment with sirolimus. Euromediterr Biomed J. 2019;14:122–4.
Galletta T, et al. Multifocal lymphangioendotheliomatosis with thrombocytopenia (MLT) with pulmonary hemorrhage. Pediatr Blood Cancer. 2019;66:S285–6.
Gastineau S, Paolella G, Talbotec C, Verkarre V, Sauvat F, Goulet O, et al. Successful use of sirolimus in children with large mesenteric lymphatic lesions. J Pediatr Gastroenterol Nutr. 2018;66:e24–5.
Gits CC, Nelson SC, Feltis BA, Alexander JQ. Multimodal therapy in the treatment of a venolymphatic malformation of the axilla and chest wall in an infant. J Vasc Surg Venous Lymphat Disord. 2014;2:451–4.
Gomez-Villegas CP, Perez-Tellez C, Ochoa-Gaviria J, Builes N. [Refractory kaposiforme hemangioendothelioma in the pediatric population: case report and literature review.]. Bol Med del Hosp Infant de Mex. 2021;78:376–84.
González-Hermosa MR, Guerra E, Tuduri I, Vicente I, López-Almaraz R. CLAPO syndrome: effective response to treatment with oral rapamycin. Dermatol Ther. 2019;32:e12991.
Gresikova M, et al. Management Kasabach-Merritt syndrome associated with vascular tumors of newborn and infants. Haemophilia. 2017;23:106.
Hodges MM, Crombleholme TM, Meyers M, Kulungowski A, Marwan AI, Nakano T, et al. Massive fetal chylothorax successfully treated with postnatal talc pleurodesis: A case report and review of the literature. J Pediatr Surg Case Rep. 2016;9:1–4.
Honnorat M, Viremouneix L, Ayari S, Guibaud L, Coste K, Claris O, et al. Early adjuvant medication with the mTOR inhibitor sirolimus in a preterm neonate with compressive cystic lymphatic malformation. Front Pediatr. 2020;8:418.
Jahnel J, Lackner H, Reiterer F, Urlesberger B, Urban C. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: from vincristine to sirolimus. Klin Padiatr. 2012;224:395–7.
Ji Y, Chen S, Yang K, Xia C, Peng S. Development of Kasabach-Merritt phenomenon following vaccination: more than a coincidence? J Dermatol. 2018;45:1203–6.
Kaylani S, Theos AJ, Pressey JG. Treatment of infantile hemangiomas with sirolimus in a patient with PHACE syndrome. Pediatr Dermatol. 2013;30:e194–7.
Kim D, Benjamin L, Wysong A, Hovsepian D, Teng J. Treatment of complex periorbital venolymphatic malformation in a neonate with a combination therapy of sirolimus and prednisolone. Dermatol Ther. 2015;28:218–21.
Koury J, Brown M, Sturtevant S, Wiley C, Felton L. Use of sirolimus in a premature neonate with kaposiform hemangioedema. J Pediatr Pharmacol Ther. 2021;26:205–9.
Kumagai C, Ozeki M, Nozawa A, Kakuda H, Fukao T. Efficacy of sirolimus in an infant with Kasabach-Merritt phenomenon. Pediatr Int. 2018;60:887–9.
Laforgia N, Schettini F, De Mattia D, Martinelli D, Ladisa G, Favia V. Lymphatic malformation in newborns as the first sign of diffuse lymphangiomatosis: successful treatment with sirolimus. Neonatology. 2016;109:52–5.
MacDonell-Yilmaz R, Renaud T. Multifocal lymphangioendotheliomatosis with thrombocytopenia: diagnosis and treatment of an infant with uncommon findings of a rare disorder. Pediatr Blood Cancer. 2018;65:S150.
Mahajan P, Margolin J, Iacobas I. Kasabach-Merritt phenomenon: classic presentation and management options. Clin Med Insights Blood Disord. 2017;10:1179545x17699849.
Manor J, Patel K, Iacobas I, Margolin JF, Mahajan P. Clinical variability in multifocal lymphangioendotheliomatosis with thrombocytopenia: a review of the literature. Pediatr Hematol Oncol. 2021;38:367–77.
Moon SJ, Baek HJ, Kim BR, Park WJ, Kim J, Lee YY, et al. Successful management of massive congenital hepatic hemangioma and systemic hypertension with sirolimus. J Pediatr Hematol Oncol. 2022;44:e424–e7.
Palla J, Iacobas I, Margolin J, Spielberg DR. Central conducting lymphatic anomaly leading to respiratory failure. Am J Respirat Crit Care Med. 2019;199:A5021.
Passarello L, Lau C, McCahon E, Popat H. A neonatal case of central conducting lymphatic anomaly successfully treated with sirolimus. Pediatr Blood Cancer. 2022;69:e29752.
Raj A, Myers S, Panigrahi A, Gupta A, Adams D. Unusual Vascular abnormalities of the neonate (puzzling presentations and diagnosis). Pediatr Blood Cancer. 2014;61:S47–S8.
Reichel A, Hamm H, Wiegering V, Wiewrodt B, Neubauer H, Ernestus K, et al. Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: successful treatment with sirolimus. J Dtsch Dermatol Ges. 2017;15:329–31.
Reinglas J, Ramphal R, Bromwich M. The successful management of diffuse lymphangiomatosis using sirolimus: a case report. Laryngoscope. 2011;121:1851–4.
Rodríguez ZN, Benavides JP. Sirolimus (rapamicina) en pacientes con hemangioendotelioma kaposiforme: Caso clínico. Rev Chil de Pediatría. 2013;84:537–44.
Rose A, et al. Generalized lymphatic anomaly in two preterm infants, diagnosis and management. J Investig Med. 2019;67:530.
Russell TB, Rinker EK, Dillingham CS, Givner LB, McLean TW. Pneumocystis jirovecii pneumonia during sirolimus therapy for kaposiform hemangioendothelioma. Pediatrics. 2018;141:S421–s4.
Triana PJ, Dore M, Nuñez VC, Jimenez JG, Miguel MF, Díaz MG, et al. Pancreatic kaposiform hemangioendothelioma not responding to sirolimus. Eur J Pediatr Surg Rep. 2017;5:e32–e5.
Tribolet S, Hoyoux C, Boon LM, Cheruy C, Demarche M, Jamblin P, et al. A not so harmless mass: Kaposiform hemangioendothelioma complicated by a Kasabach-Merritt phenomenon. Arch Pediatr. 2019;26:365–9.
Wang Y, Kong L, Sun B, Cui J, Shen W. Sirolimus for kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon in two infants. J Craniofac Surg. 2020;31:1074–7.
Wang Z, Li K, Dong K, Xiao X, Zheng S. Refractory Kasabach-Merritt phenomenon successfully treated with sirolimus, and a mini-review of the published work. J Dermatol. 2015;42:401–4.
Wlodek C, Burt H, Shaw L. A case of kaposiform haemangioendothelioma successfully and safely treated with sirolimus. Clin Exp Dermatol. 2017;42:825–7.
Yang SS, Yang M, Yue XJ, Tou JF. Sirolimus treatment for neonate with blue rubber bleb nevus syndrome: a case report. World J Clin Cases. 2021;9:6929–34.
Ying H, Qiao C, Yang X, Lin X. A case report of 2 sirolimus-related deaths among infants with kaposiform hemangioendotheliomas. Pediatrics. 2018;141:S425–s9.
Zaidi SJ, Shaik S, Agrawal C, Cossor W. First intracardiac kaposiform hemangioendothelioma in an infant resolved with sirolimus: a case report. J Pediatr Hematol Oncol. 2018;40:536–40.
Lekwuttikarn R, Josephs S, Teng JM. Successful medical management of life-threatening hepatic hemangioma in neonates. Pediatrics. 2019;144:e20191339. https://doi.org/10.1542/peds.2019-1339.
Agarwal S, Anderson BK, Mahajan P, Fernandes CJ, Margolin JF, Iacobas I. Sirolimus efficacy in the treatment of critically ill infants with congenital primary chylous effusions. Pediatr Blood Cancer. 2022;69:e29510.
Cho YJ, Kwon H, Kwon YJ, Kim SC, Kim DY, Namgoong JM. Effects of sirolimus in the treatment of unresectable infantile hemangioma and vascular malformations in children: a single-center experience. J Vasc Surg. 2021;9:1488–94.
Cirstoveanu C, Bizubac AM, Mustea C, Manolache S, Istrate-Barzan A, Sfrijan D, et al. Antiproliferative therapy with sirolimus and propranolol for congenital vascular anomalies in newborns (case reports). Exp Ther Med. 2021;22:1097.
Harbers VEM, van der Salm N, Pegge SAH, van der Vleuten CJM, Verhoeven BH, Vrancken S, et al. Effective low-dose sirolimus regimen for kaposiform haemangioendothelioma with Kasabach-Merritt phenomenon in young infants. Br J Clin Pharmacol. 2022;88:2769–81.
Iacobas I, et al. Use of sirolimus in vascular anomalies during infancy. Pediatr Blood Cancer. 2015;62:S52.
Isoldi S, Belsha D, Yeop I, Uc A, Zevit N, Mamula P, et al. Diagnosis and management of children with Blue Rubber Bleb Nevus Syndrome: a multi-center case series. Dig Liver Dis. 2019;51:1537–46.
Kai L, Wang Z, Yao W, Dong K, Xiao X. Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma. J Cancer Res Clin Oncol. 2014;140:471–6.
Karastaneva A, Gasparella P, Tschauner S, Crazzolara R, Kropshofer G, Modl M, et al. Indications and limitations of sirolimus in the treatment of vascular anomalies-insights from a retrospective case series. Front Pediatr. 2022;10:857436.
Kuo C, Warren M, Malvar J, Miller JM, Shah R, Navid F, et al. Kaposiform hemangioendothelioma of the bone in children and adolescents. Pediatr Blood Cancer. 2022;69:e29392.
Ozeki M, Nozawa A, Hori T, Kanda K, Kawamoto N, Kadota H, et al. Clinical efficacy of mTOR inhibitor for Kaposiform hemangioendotheliomas with Kasabach-Merritt phenomenon. Ann Oncol. 2017;28(supplement 9):ix101. https://doi.org/10.1093/annonc/mdx621.025.
Ozeki M, Nozawa A, Yasue S, Endo S, Asada R, Hashimoto H, et al. The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies. Orphanet J Rare Dis. 2019;14:141.
Qiu T, Yang K, Dai S, Chen S, Ji Y. Case Report: Kaposiform Hemangioendothelioma With Spinal Involvement. Front Pediatr. 2021;9:600115.
Rossler J, Baselga E, Davila V, Celis V, Diociaiuti A, El Hachem M, et al. Severe adverse events during sirolimus “off-label” therapy for vascular anomalies. Pediatr Blood Cancer. 2021;68:e28936.
Strychowsky JE, Rahbar R, O’Hare MJ, Irace AL, Padua H, Trenor CC 3rd. Sirolimus as treatment for 19 patients with refractory cervicofacial lymphatic malformation. Laryngoscope. 2018;128:269–76.
Tan X, Zhang J, Zhou S, Liu Z, Zhang T, Xia J. Successful management of steroid-resistant vascular tumors associated with the Kasabach-Merritt phenomenon using sirolimus. J Dermatol. 2018;45:580–3.
Tasani M, Ancliff P, Glover M. Sirolimus therapy for children with problematic kaposiform haemangioendothelioma and tufted angioma. Br J Dermatol. 2017;177:e344–e6.
Wang H, Guo X, Duan Y, Zheng B, Gao Y. Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma. Pediatr Dermatol. 2018;35:635–8.
Wang Z, Yao W, Sun H, Dong K, Ma Y, Chen L, et al. Sirolimus therapy for kaposiform hemangioendothelioma with long-term follow-up. J Dermatol. 2019;46:956–61.
Wu C, Song D, Guo L, Wang L. Refractory head and neck lymphatic malformation in infants treated with sirolimus: a case series. Front Oncol. 2021;11:616702.
Zaghloul N, et al. Oral rapamycin use in PTEN hamartoma syndromes and complex vascular anomalies. Pediatr Blood Cancer. 2015;62:S53.
Zhang B, Li L, Zhang N, Zhao M, Liu Y, Wei L, et al. Efficacy and safety of sirolimus in the treatment of blue rubber bleb naevus syndrome in paediatric patients. Clin Exp Dermatol. 2020;45:79–85.
Lackner H, Karastaneva A, Schwinger W, Benesch M, Sovinz P, Seidel M, et al. Sirolimus for the treatment of children with various complicated vascular anomalies. Eur J Pediatr. 2015;174:1579–84.
Gaffuri M, Torretta S, Iofrida E, Cantarella G, Borzani IM, Ciralli F, et al. Multidisciplinary management of congenital giant head and neck masses: our experience and review of the literature. J Pediatr Surg. 2019;54:733–9.
Czechowicz JA, Long-Boyle JR, Rosbe KW, Mathes EF, Frieden IJ, Shimano KA. Sirolimus for management of complex vascular anomalies - a proposed dosing regimen for very young infants. Int J Pediatr Otorhinolaryngol. 2018;105:48–51.
Giménez-Aleixandre C, Méndez-Aguirre NA, Martínez-Menchón T, Girón Vallejo Ó, Fernández-Ibieta M, Ferri-Ñíguez B, et al. [Our experience with sirolimus for the treatment of complicated vascular anomalies]. Cir Pediatr. 2019;32:28–33.
Ji Y, Chen S, Xia C, Zhou J, Jiang X, Xu X, et al. Chronic lymphedema in patients with kaposiform hemangioendothelioma: incidence, clinical features, risk factors and management. Orphanet J Rare Dis. 2020;15:313.
Ji Y, Chen S, Li L, Yang K, Xia C, Li L, et al. Kaposiform hemangioendothelioma without cutaneous involvement. J Cancer Res Clin Oncol. 2018;144:2475–84.
Funding
MP is funded by NIH grants, R03HD098482 and R21HD091718, not related to this manuscript. The NIH example had no role in the design and conduct of the study.
Author information
Authors and Affiliations
Contributions
MSP and RC collected data, analyzed the data, drafted the initial manuscript, and reviewed and revised the manuscript. SC reviewed the data, contributed to the writing of the manuscript, and revised the manuscript. II reviewed the data, contributed to the writing and revising of the manuscript, and critically reviewed the manuscript for important intellectual content. TR reviewed the data, revised the manuscript and critically reviewed the manuscript for important intellectual content. CF reviewed the data, edited the manuscript, and directed the design of figures and tables along with critically reviewing the manuscript for important intellectual content. MP conceptualized the design of the study, contributed to the writing of the manuscript, reviewed and revised the manuscript, and critically reviewed the manuscript for important intellectual content. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Cavazos, R., Patil, M.S., Gowda, S.H. et al. Sirolimus for vascular anomalies in the first year of life: a systematic review. J Perinatol (2024). https://doi.org/10.1038/s41372-024-01868-9
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41372-024-01868-9